Abstract
In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional information and clarifies potential misinterpretations.
Author supplied keywords
Cite
CITATION STYLE
Wasserman, M., Palacios, M. G., Grajales, A. G., Wilson, M., McDade, C., & Farkouh, R. (2019). Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.’” Human Vaccines and Immunotherapeutics, 15(3), 572–574. https://doi.org/10.1080/21645515.2018.1558691
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
